Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-391 vs Co-administered Atorvastatin and Ezetimibe in Healthy Volunteers
NCT04354987Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin and ezetimibe in hyperlipidemia (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to last measurable time. Started Oct 2019; status: completed.
02
Drugs
atorvastatinezetimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT04354987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354987.